Compare IDEXX Laboratories, Inc. (IDXX) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Mondaycom Ltd — how do they compare? IDEXX Laboratories, Inc. trades at $563.81 (market cap $44.48B), while Mondaycom Ltd trades at $73.54 (market cap $3.24B). The key difference: IDEXX Laboratories, Inc. is far larger — about 13.7× Mondaycom Ltd's market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| IDXX | MNDY | |
|---|---|---|
Market Cap | $44.48B | $3.24B |
Sector | Health | Technology |
52-Week High | $766.68 | $292.24 |
52-Week Low | $520.87 | $58.81 |
Enterprise Value | $45.38B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
Monday.com (MNDY) trades at $76.75, down 2.47% on the day, reflecting recent bearish pressure. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.15 versus $0.96 expected. Revenue reached $1.23 billion in 2025 with a net income margin of 9.17%. Technical indicators signal a bearish trend, with the price near key support at $75. The company announced Q2 2026 results will be reported on August 10, 2026 (Business Wire, 2026-07-20).
The investment outlook is mixed: strong analyst consensus (76% buy ratings) and a $115.50 price target suggest significant upside, but technical weakness and a high EV/EBITDA of 97.72 pose risks. Earnings growth and AI integration present opportunities, while market volatility and competitive pressures remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
